馨可宁

Search documents
HPV疫苗龙头智飞生物,净利骤降127%
凤凰网财经· 2025-08-25 13:13
以下文章来源于21世纪经济报道 ,作者21记者 权威、专业、深度、有趣!用经济思维看世界。 来源|21世纪经济报道 记者| 季媛媛 唐唯珂 编辑|张伟贤 曾经需要排队数月甚至一年的HPV疫苗,如今正静静躺在冷库中等待接种者。疫苗产业,这是一个从蓝海到红海急速转变的行业。 药企财报较为直接的展现了这一现实。根据企业披露的财报,2025年上半年,智飞生物营收同比下降73.06%至49.19亿元, 净利润亏损5.97亿元 ,同比由盈转亏;万泰生物作为国产二价疫苗的领军企业,自2020年上市以来首次出现亏损。其上半年实现营业收入8.44亿元,同比下降38.25%; 其中, 疫苗收入仅1.72亿元,同比骤降67.3% 。归母净亏损1.44亿元,同比由盈转亏,对比上年同期盈利2.6亿元;扣非净亏损进一步扩大至2.43 亿元,而上年同期扣非净利润尚有6352万元。 尽管全国已有22个省份启动HPV疫苗接种专场,覆盖超3200个接种点,但市场供需关系的根本性逆转已成为不争的事实,行业正面临前所未有的结 构性调整。 有券商医药行业分析师对21世纪经济报道记者表示,结合近期智飞生物、万泰生物等头部企业的半年度财报数据,以及行业供 ...
HPV疫苗龙头,净利骤降127%
21世纪经济报道· 2025-08-25 08:58
记者丨 季媛媛 唐唯珂 编辑丨张伟贤 曾经需要排队数月甚至一年的HPV疫苗,如今正静静躺在冷库中等待接种者。疫苗产业,这是 一个从蓝海到红海急速转变的行业。 药企财报较为直接的展现了这一现实。根据企业披露的财报,2025年上半年,智飞生物营收同 比下降73.06%至49.19亿元, 净利润亏损5.97亿元 ,同比由盈转亏;万泰生物作为国产二价疫 苗的领军企业,自2020年上市以来首次出现亏损。其上半年实现营业收入8.44亿元,同比下降 38.25%;其中, 疫苗收入仅1.72亿元,同比骤降67.3% 。归母净亏损1.44亿元,同比由盈转 亏,对比上年同期盈利2.6亿元;扣非净亏损进一步扩大至2.43亿元,而上年同期扣非净利润 尚有6352万元。 尽管全国已有22个省份启动HPV疫苗接种专场,覆盖超3200个接种点,但市场供需关系的根 本性逆转已成为不争的事实,行业正面临前所未有的结构性调整。 有券商医药行业分析师对21世纪经济报道记者表示,结合近期智飞生物、万泰生物等头部企业 的半年度财报数据,以及行业供需格局的演变趋势,可以看到当前HPV疫苗市场的"寒冬"本质 上是需求透支后的理性回归与行业竞争加剧共同作用 ...
研究发现:国产二价HPV疫苗“馨可宁” 十年保护力优异
Ge Long Hui· 2025-08-24 01:01
Core Viewpoint - The research conducted by Professor Xia Ning Shao's team at Xiamen University highlights the long-term protective effects and immune durability of the domestically developed bivalent HPV vaccine "Xinkening" over a ten-year period [1] Group 1: Vaccine Efficacy - The bivalent HPV vaccine "Xinkening," developed in collaboration with Wantai Biological Pharmacy, was approved for market in 2019, making it the first HPV vaccine in China and the fourth globally [1] - Previous studies indicated a 100% protection rate against HPV-16/18 related high-grade precancerous lesions within 5.5 years post-vaccination, and a 97.3% protection rate against related six-month persistent infections [1] - The ten-year study shows an 87.4% protection rate against high-grade precancerous lesions and a 97.0% protection rate against six-month persistent infections [1] Group 2: Immune Response - Nearly all vaccinated individuals still possess neutralizing antibodies against HPV-16/18 ten years post-vaccination, with levels significantly higher than those resulting from natural infection [1] - The research confirms that the "Xinkening" vaccine remains effective for at least ten years, providing strong support for its widespread application [1]
上半年净利暴跌155%万泰生物业绩“变脸”
Xin Lang Cai Jing· 2025-08-22 00:06
Group 1 - Wante Bio reported its first loss since going public, with a net loss of 144 million yuan in the first half of 2025, a year-on-year decline of 155.3% [1][2] - The company's revenue for the first half of 2025 was 844 million yuan, down 38.25% compared to the previous year [1][2] - The decline in performance is attributed to market adjustments in the vaccine sector and the expansion of the age range for the nine-valent HPV vaccine, leading to lower-than-expected sales [1][2] Group 2 - The vaccine segment, which previously contributed significantly to Wante Bio's revenue, has become a major factor in the company's losses [1][2] - In 2022, the approval of Watson Bio's two-valent vaccine "Wozhehui" further intensified market competition, impacting Wante Bio's market share [2][3] - Wante Bio's revenue fell by 59.25% to 2.245 billion yuan in 2024, only one-fifth of its peak revenue in 2022, with net profit declining by 91.49% to 106 million yuan [2][3] Group 3 - Wante Bio's nine-valent HPV vaccine "Xinkening 9" was approved in June 2025, becoming the first in China and the second globally, priced at 499 yuan per dose [3] - The competitive landscape is heating up, with Merck's nine-valent HPV vaccine launching promotional activities, and other domestic competitors also preparing to enter the market [3][4] - The overall HPV vaccine market is experiencing a cooling trend, with a significant drop in demand and prices, contrasting with previous high demand [3][4]
预亏1.6亿元,万泰生物HPV疫苗能否靠价格战突围
2 1 Shi Ji Jing Ji Bao Dao· 2025-07-15 05:18
Core Viewpoint - The domestic HPV vaccine market is undergoing a brutal transformation from a blue ocean to a red ocean, as evidenced by the drastic price drop of a leading vaccine product from 329 yuan to 27.5 yuan within three years [1] Financial Performance - Wantai Bio (603392.SH) expects a net profit loss of 130 million to 160 million yuan for the first half of 2025, with a significant decline compared to a net profit of 260 million yuan in the same period last year [1][3] - The company's revenue for 2024 was 2.245 billion yuan, a year-on-year decrease of 59.25%, marking the lowest revenue since 2020 [3] - The net profit attributable to the parent company for 2024 was 106 million yuan, down 91.49% year-on-year, with a non-recurring net profit of -186 million yuan, a decline of 117.29% [3] Market Dynamics - The HPV vaccine market is becoming increasingly competitive, with Wantai Bio's two-valent HPV vaccine facing pressure from imported nine-valent vaccines and other domestic competitors [2][4] - The price of Wantai Bio's two-valent HPV vaccine has dropped significantly due to government procurement policies, with the lowest bid price falling to 63 yuan per dose [5][7] - The introduction of Wantai Bio's nine-valent HPV vaccine, priced at 499 yuan, aims to capture market share but faces strong competition from Merck's Gardasil 9 [8][13] Strategic Response - Wantai Bio is betting on the success of its nine-valent HPV vaccine to offset losses from its two-valent vaccine, which has seen a significant decline in sales [1][2] - The company has invested approximately 1 billion yuan in research and development for the nine-valent vaccine, alongside 590 million yuan for expansion projects [8][15] - The company is also pursuing WHO PQ certification for its nine-valent vaccine to facilitate international market entry [15] Industry Trends - The global HPV vaccine market has seen a compound annual growth rate (CAGR) of 19% since 2019, highlighting the increasing demand for HPV vaccination [4] - The World Health Organization has emphasized the importance of HPV vaccination in its strategy to eliminate cervical cancer globally, which aligns with China's action plan to promote HPV vaccination [9]
浙江十大富豪创业档案
Sou Hu Cai Jing· 2025-06-28 14:13
Group 1: Zhejiang Business Representatives - The entrepreneurial trajectories of ten Zhejiang business representatives reflect a micro-epic of individual resonance with the times, showcasing their resilience and technological faith in a globalized context [1] - These entrepreneurs span various industries, from beverage empires to e-commerce and renewable energy, illustrating a collective narrative of adaptation and innovation [1] Group 2: Notable Entrepreneurs - Zhong Shanshan, known as the "Water King," transformed China's drinking water landscape and successfully launched the first domestic HPV vaccine, with his company Wan Tai Biologics now valued over 100 billion [3][4] - Huang Zheng, a math genius and founder of Pinduoduo, utilized a group-buying model to tap into the "five-ring" consumer base, achieving a GMV of over 300 billion USD in three years with Temu [4] - Jack Ma, founder of Alibaba, transitioned from a disruptive internet figure to an ecological steward, focusing on environmental projects like desert afforestation while maintaining a low public profile [6] - Ding Lei, CEO of NetEase, transformed the company from an email service to a cultural empire, emphasizing innovation driven by passion and hands-on involvement in product development [7] - Li Shufu, founder of Geely, successfully acquired Volvo and expanded into electric vehicles, demonstrating a practical approach to the automotive industry [8] - Zong Qinghou, founder of Wahaha, built a beverage empire through a militarized management style and innovative marketing strategies, now adapting to younger consumer trends [9] - Lin Jianhua and Zhang Hong, a husband-and-wife team, achieved over 50% market share in the photovoltaic industry with their innovative EVA film technology [10] - Luo Ligong, founder of Hoshine Silicon Industry, adopted a vertical integration strategy to dominate the silicon material market, capturing 20% of global industrial silicon capacity [11] - Ruan Liping and Ruan Xueping, founders of Bull Group, focused on quality control in the electrical accessories market, achieving a market share of 65% in safety sockets [13] - Zhang Hejun, founder of Deye, successfully transitioned from traditional manufacturing to renewable energy, with his company's inverter products ranking among the top five globally [14]
万泰生物颓了,九价能救?
Hu Xiu· 2025-06-06 10:57
Core Viewpoint - Wantai Biological's 9-valent HPV vaccine has been approved in China, breaking the long-standing foreign monopoly and potentially reversing the company's declining revenue and profit trend [1][2]. Group 1: Company Performance - Wantai Biological's revenue and profit have been declining for several years, with reported revenues of 111.85 billion yuan in 2022, 55.11 billion yuan in 2023, and a projected 22.45 billion yuan in 2024. Net profits were 47.36 billion yuan, 12.48 billion yuan, and 1.06 billion yuan for the same years [4]. - In Q1 2025, the company continued to face challenges, with revenue of 4.01 billion yuan, a year-on-year decline of 46.76%, and a net loss of 0.53 billion yuan, a staggering decline of 141.98% [4]. Group 2: Market Dynamics - The approval of the 9-valent HPV vaccine is expected to boost Wantai's performance in 2025, as it can capture market share from Merck, which currently has the only competing product [8]. - The 9-valent HPV vaccine offers broader protection compared to the 2-valent version, which may enhance its market appeal [8]. Group 3: Competitive Landscape - The domestic HPV vaccine market has become increasingly competitive, with prices for the 2-valent HPV vaccine dropping significantly from 329 yuan to 86 yuan, leading to a substantial revenue decline for Wantai's vaccine segment [6][10]. - The market is expected to see more competitors entering with their own 9-valent HPV vaccines by 2026, which could lead to further price wars and impact Wantai's ability to maintain growth [15][16]. Group 4: Future Outlook - While the approval of the 9-valent HPV vaccine is a positive development for Wantai, the long-term growth outlook remains uncertain due to potential pricing pressures and increased competition from other domestic manufacturers [16].
国产九价HPV疫苗来了 你想打吗
经济观察报· 2025-06-05 21:03
Core Viewpoint - The approval of Wantai Biological's nine-valent HPV vaccine marks a significant development in the domestic HPV vaccine market, but the company faces challenges in sales due to increased competition and market saturation [2][5]. Group 1: Market Dynamics - The nine-valent HPV vaccine has become widely available, with sales pressure on Merck and its domestic distributor Zhifei Biological, raising questions about Wantai Biological's ability to sell its product [2][7]. - The market for HPV vaccines has seen a dramatic increase in supply, with the number of approved doses rising from 3.32 million in 2019 to 36.55 million in 2023, leading to a decrease in demand and sales pressure for existing products [7][8]. Group 2: Financial Performance - Wantai Biological's revenue from its two-valent HPV vaccine peaked at over 8.49 billion yuan in 2022 but fell to 5.51 billion yuan in 2023, with projections for further decline in 2024 [5]. - Analysts predict that the nine-valent HPV vaccine could become a core driver of Wantai Biological's performance, with potential peak sales reaching 22.8 billion yuan if penetration among eligible women exceeds 50% [5][8]. Group 3: Competitive Landscape - Wantai Biological's nine-valent HPV vaccine is the first domestically produced version and the second globally, but it will face stiff competition from Merck's Gardasil 9 and other emerging products from companies like Shanghai Bowei and Beijing Kanglaweishi [2][9]. - The market for HPV vaccines is expected to become increasingly competitive, with several companies developing higher-valent vaccines, which may further challenge Wantai Biological's market position [9].
男性也需警惕HPV感染:疫苗适应症扩大,如何实现“男女共防”?
2 1 Shi Ji Jing Ji Bao Dao· 2025-05-28 09:34
Group 1: HPV Infection and Public Awareness - HPV infection is a significant public health issue affecting both men and women, with a notable lack of awareness regarding male HPV infection risks [2][4] - In China, cervical cancer cases reached approximately 110,000 in 2020, with around 59,000 deaths, making it the second highest burden of cervical cancer globally [2] - Misconceptions persist about male HPV infection, leading to underestimation of risks and a lack of urgency in vaccination [4][5] Group 2: HPV Vaccination Developments - The nine-valent HPV vaccine has received approval for use in males aged 16-26 in China, marking a significant step towards gender-inclusive HPV prevention [3] - Currently, there are two HPV vaccines available for males: a four-valent vaccine for ages 9-26 and a nine-valent vaccine for ages 16-26, with the latter providing broader protection [6] Group 3: Market Demand and Future Projections - The HPV vaccine market in China is projected to grow from 13.5 billion yuan in 2020 to 69 billion yuan by 2030, with the nine-valent vaccine expected to capture the largest market share [8] - Despite the potential for growth, the current vaccination rate remains low, with only about 21% of women vaccinated since the introduction of the HPV vaccine in China [9][10] - There is a significant unmet demand for HPV prevention among men, which presents a substantial market opportunity as health awareness increases [10]
HPV疫苗企业一季度业绩集体失速
Zhong Guo Jing Ying Bao· 2025-05-18 23:22
Core Viewpoint - The performance of major Chinese vaccine companies, including Wantai Biological Pharmacy (万泰生物), Zhifei Biological Products (智飞生物), and Watson Bio (沃森生物), has significantly declined in Q1 2025, primarily due to a shrinking self-paid market for HPV vaccines amid economic pressures [1] Group 1: Company Performance - Wantai Biological reported a revenue of 401 million yuan in Q1 2025, a year-on-year decrease of 46.76%, with a net loss of 52.78 million yuan [1] - Zhifei Biological's revenue fell to 2.374 billion yuan, down 79.16% year-on-year, resulting in a net loss of 305 million yuan [1] - Watson Bio achieved a revenue of 462 million yuan, a decline of 22.93%, with a net profit of 2.65 million yuan, down 81.27% [1] Group 2: Market Dynamics - The HPV vaccine market is experiencing a significant contraction, with a 61.57% year-on-year drop in the total number of HPV vaccine batches approved for sale in 2024 [3] - The two-valent HPV vaccine's sales revenue for Wantai Biological plummeted by 84.69% to 606 million yuan in 2024, influenced by price reductions and increased competition from the nine-valent HPV vaccine [3][4] - The price of HPV vaccines has drastically decreased, with the two-valent vaccine's procurement price dropping from over 300 yuan to 27.5 yuan in Shandong province, reflecting a nearly 90% decline [7] Group 3: Competitive Landscape - The introduction of the nine-valent HPV vaccine has intensified competition, with consumers favoring higher-priced vaccines, leading to a sharp decline in demand for the two-valent vaccine [4] - Zhifei Biological, as the exclusive agent for Merck's HPV vaccines, faced a 95.49% drop in the issuance of four-valent HPV vaccines in 2024, exacerbated by Merck's suspension of supplies to China [4][5] - The price war in the HPV vaccine market has severely compressed profit margins, with Wantai Biological's vaccine segment gross margin falling from 91.6% in 2022 to 70.4% in 2024 [7] Group 4: Future Outlook - The development of domestic nine-valent HPV vaccines is accelerating, with several companies, including Wantai Biological, advancing their clinical trials [8] - The potential introduction of male-targeted HPV vaccines may open new growth avenues, as Merck's four-valent HPV vaccine has been approved for male use [9]